Patent 9676760 was granted and assigned to Gilead Sciences on June, 2017 by the United States Patent and Trademark Office.
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: